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Abstract
Background: Cardiovascular disease morbidity-mortality is greater in people with type 2 diabetes mellitus or
metabolic syndrome. The purpose of this study was to evaluate the yearly evolution of organ damage markers in
diabetes or metabolic syndrome, and to analyze the associated factors.
Methods: An observational prospective study was carried out in the primary care setting, involving 112 patients:
68 diabetics and 44 subjects with metabolic syndrome, subjected to 12 months of follow-up. Measurements:
traditional cardiovascular risk factors (blood pressure, blood glucose, lipids, smoking, body mass index (BMI) and)
and non-traditional risk factors (waist circumference, hsC Reactive Protein and fibrinogen); subclinical vascular
(carotid intima-media thickness, pulse wave velocity and ankle/brachial index), cardiac (Cornell voltage-duration
product), renal organ damage (creatinine, glomerular filtration and albumin/creatinine index), and antihypertensive
and lipid-lowering drugs.
Results: At baseline, the diabetics presented a mean age of 59.9 years, versus 55.2 years in the subjects with
metabolic syndrome (p = 0.03). Diastolic blood pressure, total cholesterol and HDL-cholesterol were lower among
the patients with diabetes, while blood glucose and HbA1c, as well as antihypertensive and lipid-lowering drug
use, were greater. At evaluation after one year, the diabetics showed a decrease in BMI (-0.39), diastolic blood
pressure (-3.59), and an increase in fibrinogen (30.23 mg/dL), ankle/brachial index (0.07) and the number of patients
with ankle/brachial index pathologic decreased in 6. In turn, the patients with metabolic syndrome showed an
increase in HDL-cholesterol (1-91 mg/dL), fibrinogen (25.54 mg/dL), Cornell voltage-duration product (184.22 mm/
ms), ankle/brachial index (0.05) and the use of antihypertensive and lipid-lowering drugs, and a reduction in serum
glucose (3.74 mg/dL), HOMA, systolic (-6.76 mmHg), diastolic blood pressure (-3.29 mmHg), and pulse wave
velocity (-0.72 m/s). The variable that best predicted a decrease in pulse wave velocity in subjects with metabolic
syndrome was seen to be an increase in antihypertensive drug use.
Conclusions: The annual assessment of cardiovascular risk factors and the decrease in pulse wave velocity was
more favorable in the patients with metabolic syndrome, probably influenced by the increased percentage of
subjects treated with antihypertensive and lipid lowering drugs in this group.
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Cardiovascular disease morbidity-mortality is greater in
people with type 2 diabetes mellitus (T2DM) or meta-
bolic syndrome [1-4]. The presence of target organ
damage (TOD) increases the risk of cardiovascular com-
plications independently of the existing estimated risk
[5,6]. In this context, left ventricular hypertrophy (LVH),
assessed according to electrocardiographic criteria,
increases the risk of coronary complications and stroke
[7,8]. The worsening of renal function, assessed by
increased creatinine levels, a drop in glomerular filtration
rate (GFR), or an increase in protein excretion in urine,
increases the risk of cardiovascular diseases [9,10]. Per-
ipheral arterial disease, evaluated by the ankle/brachial
index (ABI), is correlated to the development of coronary
complications, the incidence of stroke, and cardiovascular
mortality [11]. The ultrasound measurement of common
carotid artery intima-media thickness (IMTCc) allows
the evaluation of vascular structure and the early detec-
tion of atherosclerotic lesions, representing a good pre-
dictor of future vascular events and a surrogate marker
of atherosclerosis [12,13]. IMTCc in T2DM is 0.13 mm
greater than in the controls. This implies an age incre-
ment of 10 years, and is associated to a 40% increase in
cardiovascular risk [14]. Likewise, an increase in arterial
stiffness, assessed by pulse wave velocity (PWV), predicts
future cardiovascular events and mortality of any cause
in both hypertensive subjects and in the general popula-
tion [15,16], though the role played in individuals with
Metabolic syndrome [17,18] or T2DM is not clear [19].
Thus, it is important to know the evolution of the differ-
ent cardiovascular risk factors and of cardiac, renal and
vascular TOD, as well as the corresponding conditioning
factors in patients with diabetes or metabolic syndrome.
We postulate that the evolution of the different risk
factors and target organ damage is similar in both groups,
since the antihypertensive drugs, lipid lowering drugs and
metformin with beneficial effects upon blood pressure,
lipid profile and target organ damage, are used in greater
percentages in the group of patients with T2DM.
The purpose of this study was to evaluate the yearly
evolution of organ damage markers in diabetes or meta-
bolic syndrome, and to analyze the associated factors.
Materials and methods
Study design and population
A prospective observational study was carried out in a
primary care setting. Using consecutive sampling, we
included 112 patients with type 2 diabetes mellitus
(T2DM) (n = 68) (defined using the American Diabetes
Association criteria [20]) or metabolic syndrome (n =
44)(defined according to the National Cholesterol Edu-
cation Program, ATP III1 definition [21]) from a
population of 46,000 people corresponding to two pri-
mary care centers (including 2412 diagnosed with dia-
betes and 4100 with metabolic syndrome). The study
included patients with diabetes or metabolic syndrome
who visited their family doctor from January 2009 to
January 2010, with none of the following exclusion cri-
teria: patients unable to comply with the protocol
requirements (psychological and/or cognitive disorders,
failure to cooperate, educational limitations and pro-
blems for understanding written language, failure to sign
the informed consent document); patients participating
or programmed to participate in a clinical trial during
the study; and patients with serious comorbidities repre-
senting a threat to life over the subsequent 12 months.
The sample size was estimated to detect as statistically
significant a difference in carotid IMT ≥ 0.05 mm
between baseline and first year evaluation. Accepting an
alpha risk of 0.05 and a beta risk of 0.2 in a two-sided
test, and assuming a standard deviation of 0.11 mm, 40
subjects were seen to be necessary, assuming a dropout
rate of 5%. The study was approved by an independent
ethics committee of Salamanca University Hospital
(Spain), and all participants gave written informed con-
sent according to the general recommendations of the
Declaration of Helsinki [22]. The LOD-DIABETES
Study comprises a cohort of 68 diabetics and 44 subjects
with metabolic syndrome subjected to annual evaluation
of vascular, renal and cardiac target organ damage
(TOD).
Measurements
A detailed description has been published elsewhere of
how the clinical data were collected, the anthropometric
measurements were made, blood pressure was recorded,
TOD was assessed, and the analytical parameters were
obtained [23].
Blood pressure
Office or clinical blood pressure measurement was
obtained by performing three measurements of systolic
(SBP) and diastolic blood pressure (DBP), using the
average of the last two, with a validated OMRON model
M7 sphygmomanometer (Omron Health Care, Kyoto,
Japan), and following the recommendations of the Eur-
opean Society of Hypertension [24]. The mean of the
last two measurements obtained by the nurse of the
research unit from the arm with high blood pressure
was used for the study.
Vascular assessment
Assessment of carotid intima-media thickness (IMT)
Carotid ultrasound to assess IMT was performed by two
investigators trained for this purpose before starting the
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the study, using the intraclass correlation coefficient,
which showed values of 0.974 (95%CI: 0.935 to 0.990)
for intra-observer agreement on repeated measurements
in 20 subjects, and 0.897 (95%CI: 0.740 to 0.959) for
inter-observer agreement. According to the Bland-Alt-
man analysis, the limit of inter-observer agreement was
0.022 (95%CI: -0.053 to 0.098), and the limit of intra-
observer agreement was 0.012 (95%CI: -0.034 to 0.059).
A Sonosite Micromax ultrasound device paired with a
5-10 MHz multifrequency high-resolution linear trans-
ducer with Sonocal software was used for performing
automatic measurements of IMT in order to optimize
reproducibility. Measurements were made of the com-
mon carotid after the examination of a longitudinal sec-
tion of 10 mm at a distance of 1 cm from the
bifurcation, performing measurements in the anterior or
proximal wall, and in the posterior or distal wall in the
lateral, anterior and posterior projections - following an
axis perpendicular to the artery to discriminate two
lines: one corresponding to the intima-blood interface
and the other to the media-adventitious interface. A
total of 6 measurements were obtained of the right caro-
tid and another 6 of the left carotid, using average
values (average IMT) and maximum values (maximum
IMT) calculated automatically by the software. The
measurements were obtained with the subject lying
down, with the head extended and slightly turned oppo-
site to the exploratory side, following the recommenda-
tions of the Manheim Carotid Intima-Media Thickness
Consensus [25]. The average IMT was considered
abnormal if > 0.90 mm, or if there were atherosclerotic
plaques with a diameter 1.5 mm or a focal increase of
0.5 mm or 50% of the adjacent IMT.
Evaluation of peripheral artery involvement
This was evaluated using the ankle-brachial index (ABI).
The pressure in the extremities was measured using a
portable Doppler system Minidop Es-100Vx (Hadeco,
Inc. Arima, Miyamae-ku, Kawasaki, Japan) applying the
probe at the anterior or posterior tibial artery at an
angle of approximately 60° to the direction of blood
flow. The ABI was calculated separately for each foot by
dividing the greater of the two systolic pressures in the
ankle by the greater of the two systolic pressures in the
arm. TOD was considered if ABI < 0.9 [24].
Pulse wave velocity (PWV)
This parameter was estimated using the SphymgoCor
System (AtCor Medical Pty Ltd Head Office, West
Ryde, Australia), with the patient in the supine position.
The pulse waves of the carotid and femoral arteries
were analyzed, estimating the delay with respect to the
ECG wave and calculating the corresponding PWV. Dis-
tance measurements were taken with a measuring tape
from the sternal notch to the carotid and femoral
arteries at the sensor location. TOD was considered if
PWV > 12 m/s [24].
Renal assessment
Kidney damage was assessed by measuring plasma crea-
tinine concentration. Glomerular filtration rate (GFR)
was estimated according to the CKD-EPI (Chronic Kid-
ney Disease Epidemiology Collaboration) [26] for Cauca-
sians, and proteinuria was assessed from the albumin/
creatinine ratio following the ESH 2007 criteria. TOD
was defined as plasma creatinine ≥ 1 . 3m g / 1 0 0m li n
men and ≥ 1.2 mg/100 ml in women; GFR < 60 ml/min;
or albumin/creatinine ratio ≥ 22 mg/g in men and ≥ 31
mg/g in women [24].
Cardiac assessment
The electrocardiographic examination was performed
using a General Electric MAC 3.500 ECG System (Gen-
eral Electric, Niskayuna, NY, USA) that automatically
measures the voltage and duration of waves and esti-
mates the criteria of the Cornell voltage-duration pro-
duct (Cornell VDP) [27]. TOD was defined according to
the 2007 European Society of Hypertension/European
Society of Cardiology guidelines criteria [24].
Information about kilocalorie intake was collected
using the food frequency questionnaire of the University
of Navarre, validated for Spain [28]. In order to classify
patients as active or non-active cases, we considered
sedentary patients as those failing to follow the recom-
mendations of the Centers for Disease Control and Pre-
vention: accumulation of at least 30 min of moderate
physical activity 5 or more days a week, or three or
more sessions of intense activity a week, each with a
minimum duration of 30 min. The individuals perform-
ing the different tests were blinded to the clinical data
of the patient.
Statistical analysis
Continuous variables are expressed as the mean ± stan-
dard deviation, and qualitative variables as frequency
distributions. To analyze the changes in the different
variables between the two assessments, use was made of
the Student t-test for paired quantitative data, with
application of the McNemar test for qualitative vari-
ables. The multivariate analysis involved a stepwise mul-
tiple linear regression model, using as dependent
variables those resulting from the differences in evalua-
tion of the target organ lesions between the two mea-
sures (Difference IMT = IMT2-IMT1, Difference PWV
= PWV2-PWV1, Difference PDVCORNELL =
PDVCORNELL2- PDVCORNELL1, and Difference ABI
= ABI2-ABI1). After adjusting for age and sex, we
included as independent variables in the analysis for
each of the two groups those variables obtained from
the differences between the two evaluations that reached
statistical significance in the diabetes group (BMI,
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group (HDL-cholesterol, baseline blood glucose, fibrino-
g e n ,H O M A ,S B P ,D B P ,a n t i h y p e r t e n s i v ed r u g sa n d
lipid-lowering drugs). In a second step using the step-
wise method, only those variables which reached statisti-
cal significance in the regression model remained in the
r e s u l to ft h ea n a l y s i s .T h ed a t aw e r ea n a l y z e du s i n gt h e
SPSS version 18.0 statistical package (SPSS Inc., Chi-
cago, Illinois, USA). A value of p < 0.05 was considered
statistically significant.
Results
Throughout the year of study of follow-up, two males
died as a result of acute myocardial infarction, one with
T2DM and the other with metabolic syndrome (aged 76
and 65 years, respectively).
At the baseline evaluation, the diabetic patients were
4.5 years older on average (p = 0.03), with a greater per-
centage of past cardiovascular events, higher C-reactive
protein, fibrinogen and HOMA values, and less favorable
vascular, renal and cardiac damage indicators,
presentando un mayor porcentaje de pacientes activos
(45.60% vs 29.50%). In contrast, the subjects with meta-
bolic syndrome showed a poorer lipid profile, and poorer
obesity and blood pressure parameters, though for most
of the analyzed variables the differences failed to reach
statistical significance. Mean antihypertensive and lipid-
lowering drug use was greater among the patients with
T2DM. La ingesta calórica día fue similar en los dos gru-
pos (2449.29 ± 726.42 vs 2477.08 ± 849.93).
Evaluation after one year, the behavior of the risk fac-
tors was similar to that of the data commented above,
with a tendency towards improvement of the obesity,
lipid profile and blood pressure parameters in both
groups. However, IMTCc was seen to equalize in both
groups, PWV decreased, and the Cornell voltage-dura-
tion product increased in the patients with metabolic
syndrome. Antihypertensive and lipid-lowering drug use
increased in the subjects with metabolic syndrome
(Tables 1, 2, 3 and 4).
On analyzing the differences in the risk factors, vascu-
lar, renal and cardiac TOD and antihypertensive and
Table 1 General demographic and clinics characteristics in Diabetics
Variables Basal evaluation Annual review Differences IC 95% p Value
Number (%) 68 (60.70) 67 (58.90)
Age (years) 59.91 ± 10.08 60.91 ± 10.08
Males n (%) 43 (63.20) 42 (62.68)
Years of evolution 5.41 ± 4.19 6.41 ± 4.19
Smokers n (%) 16 (23.50) 16(25.00)
Ischemic heart disease n (%) 8 (11.80) 8 (12.50)
Cerebrovascular disease n (%) 2 (2.90) 2(2.50)
BMI (kg/m
2) 30.08 ± 4.96 29.71 ± 5.28 -0.39 -0.69 to -0.08 0.014
Waist circumference (cm) 102.93 ± 12.73 101.63 ± 13.74 -1.30 -2.08 to 0.11 0.078
Total Cholesterol (mg/dL) 187.54 ± 33.97 185.84 ± 37.10 -1.70 -10.36 to 5.43 0.534
Tryglicerides (mg/dL) 143.90 ± 68.25 141.63 ± 76.03 -2.24 -14.90 to 13.62 0.929
LDL cholesterol (mg/dL) 108.61 ± 28.45 107.95 ± 28.91 -0.66 -8.33 to 5.28 0.656
HDL cholesterol (mg/dL) 48.61 ± 11.69 48.48 ± 12.09 -0.13 -2.06 to 1.52 0.764
Serum glucose (mg/dL) 126.68 ± 35.34 132.48 ± 45.81 5.80 -0.45 to 14.54 0.065
HbA1c (%) 6.83 ± 1.17 7.01 ± 1.33 0.18 -0.07 to 0.41 0.159
Serum creatinine, (mg/dL) 0.86 ± 0.17 0.86 ± 0.21 0.00 -0.04 to 0.04 1.000
hs-c-reactive (mg/dL) 0.34 ± 0.51 0.32 ± 0.42 -0.02 -0.17 to 0.10 0.631
Fibrinogen (mg/dL) 337.16 ± 61.16 365.82 ± 93.23 26.66 6.18 to 54.28 0.015
HOMA-IR 3.24 ± 2.69 3.34 ± 3.82 1.00 -0.38 to 1.24 0.287
Office SBP (mm Hg) 136.13 ± 19.09 132.44 ± 18.80 -3.69 -8.16 to 1.16 0.139
Office DBP (mm Hg) 82.64 ± 11.59 78.92 ± 9.82 -3.72 -6.08 to -1.10 0.005
Office PP, mm Hg 53.88 ± 14.38 54.69 ± 17.64 0.81 -2.65 to 4.27 0.640
Office HR 72.10 ± 12.43 70.56 ± 11.06 -1.54 -2.81 to 1.36 0.488
Mean Antihypertensive Drugs 1.51 ± 1.15 1.57 ± 1.21 0.06 -0.17 to 0.28 0.603
Antihypertensive Drugs, n (%) 52 (76.50) 51(75.00) -1.5 -1.4 to 1.5 0.625
Mean Lipid lowering drugs 0.68 ± 0.56 0.66 ± 0.56 -0.01 -0.10 to 0.07 0.742
Lipid lowering drugs, n (%) 45 (66.20) 44(64.70) -1.5 -1.8 to 1.6 0.687
Data for qualitative variables are expressed as N: number (%) and quantitative variables as mean ± standard deviation.
BMI: body mass index; LDL: low density lipoprotein; HDL: high density lipoprotein; HbA1C: glycosylated hemoglobin; HOMA-IR: homeostasis model assessment
insulin resistance; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; PP: pulse pressure; HR: heart rate.
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after one year, a significant decrease was noted in BMI
and diastolic blood pressure, together with an increase
in fibrinogen and ABI in the patients with T2DM. In
contrast, the patients with an initial diagnosis of Meta-
bolic syndrome showed a significant drop in systolic and
diastolic blood pressure, HOMA index and PWV, and
an increase in HDL-Cholesterol, serum glucose, fibrino-
gen, ABI, Cornell voltage-duration product and antihy-
pertensive and lipid-lowering drug use (Tables 1, 2, 3
and 4, Figure 1).
In the multiple regression analysis, the variables that
remained in the equation explaining the changes in
TOD parameters in patients with Metabolic syndrome
were: the difference in antihypertensive drug use in
PWV (R
2 =0 . 2 3 5 ) ,a n dt h ed i f f e r e n c ei na n t i h y p e r t e n -
sive and lipid-lowering drug use in relation to the Cor-
nell voltage-duration product (R
2 =0 . 2 5 8 ) .H o w e v e r ,i n
the diabetic patients and following the same regression
analysis, the variable remaining in the model explaining
the differences in PWV (R
2 =0 . 1 3 3 )a n dC o r n e l l
voltage-duration product (R
2 = 0.104) was seen to be
the difference in systolic blood pressure (Table 5).
Discussion
The data obtained describe the evolution of to conven-
tional and non-conventional risk factors and of las TOD
vascular, cardiac and renal damage in patients with
T2DM or metabolic syndrome over one year of follow-
up. We observed a increase in ABI in the diabetics. In
contrast, the patients with metabolic syndrome experi-
enced an increase in ABI and Cornell voltage-duration
product, and a decrease in PWV, probably as a result of
an increased use of antihypertensive drugs.
T h em e a nI M T C ci nt h ep a t i e n t sw i t hT 2 D Mw a s
0.76 mm, same in the two assessments. This being simi-
lar (taking age into account) to the data obtained in
Caucasians with T2DM in the metaanalysis published by
Brohall et al. [14]. The mean IMTCc in the two evalua-
tions among the subjects with Metabolic syndrome was
0.75 mm and greater than the data of the Carmela study
(0.69 mm). These differences are probably explained by
Table 2 General demographic and clinics characteristics in Metabolic Syndrome
Variables Basal evaluation Annual review Differences IC 95% p Value
Number (%) 44 43
Age (years) 55.20 ± 12.49 56.20 ± 12.49
Males n (%) 28 (63.60) 27 (62.79)
Years of evolution 1.58 ± 2.06 1.58 ± 2.06
Smokers n (%) 9 (20.50) 9 (20.93)
Ischemic heart disease n (%) 2 (4.50) 2 (4.65)
Cerebrovascular disease n (%) 0 (0.00) 0 (0.00)
BMI (kg/m
2) 31.08 ± 3.52 30.82 ± 4.05 -0.26 -0.61 to 0.05 0.094
Waist circumference (cm) 104.75 ± 9.76 104.79 ± 8.98 0.04 -1.34 to 1.52 0.896
Total Cholesterol (mg/dL) 218.95 ± 44.15 208.51 ± 41.26 -10.44 -21.60 to 0.06 0.051
Tryglicerides (mg/dL) 167.68 ± 53.07 151.02 ± 83.70 -16.66 -38.47 to 7.54 0.182
LDL cholesterol (mg/dL) 140.25 ± 39.67 130.56 ± 35.94 -9.69 -19.85 to 0.04 0.051
HDL cholesterol (mg/dL) 45.18 ± 10.96 47.38 ± 11.42 2.20 0.16 to 3.65 0.033
Serum glucose (mg/dL) 92.57 ± 11.78 88.91 ± 12.52 -3.66 -7.02 to -0.47 0.026
HbA1c 5.59 ± 0.66 5.67 ± 0.32 0.08 -0.11 to 0.30 0.367
Serum creatinine, (mg/dL) 0.89 ± 0.16 0.90 ± 0.19 0.01 -0.03 to 0.05 0.575
hs-c-reactive (mg/dL) 0.26 ± 0.21 0.27 ± 0.25 0.01 -0.04 to 0.05 0.687
Fibrinogen (mg/dL) 327.05 ± 59.07 345.16 ± 66.64 18.11 6.87 to 44.21 0.009
HOMA-IR 2.96 ± 1.82 2.22 ± 1.33 -0.74 -1.35 to -0.27 0.004
Office SBP (mm Hg) 142.43 ± 12.46 134.95 ± 15.52 -7.48 -11.35 to -2.18 0.005
Office DBP (mm Hg) 88.63 ± 9.61 84.92 ± 10.26 -3.71 -6.32 to -0.26 0.034
Office PP, mm Hg 54.23 ± 11.35 50.77 ± 12.78 -3.46 -6.96 to 0.73 0.109
Office HR 74.23 ± 12.23 72.44 ± 11.66 -1.79 -3.78 to 0.94 0.232
Mean Antihypertensive Drugs 0.82 ± 1.04 1.34 ± 1.20 0.52 0.21 to 0.83 0.002
Antihypertensive Drugs, n (%) 21 (47.70) 31 (72.10) 24.40 -44 to 40 0.001
Mean Lipid lowering drugs 0.30 ± 0.46 0.43 ± 0.55 0.13 0.03 to 0.24 0.013
Lipid lowering drugs, n (%) 13 (29.50) 19 (44.20) 14.70 -3.5 to 450.0 0.031
Data for qualitative variables are expressed as N: number (%) and quantitative variables as mean ± standard deviation.
BMI: body mass index; LDL: low density lipoprotein; HDL: high density lipoprotein; HbA1C: glycosylated hemoglobin; HOMA-IR: homeostasis model assessment
insulin resistance; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; PP: pulse pressure; HR: heart rate.
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Variables Basal evaluation Annual review Differences IC 95% p Value
Vascular
Carotid IMT men average (mm) 0.76 ± 0.12 0.76 ± 0.10 0.00 -1 to 1 0.82
Carotid IMT men average ≥ 90 mm, n (%) 17 (25.00) 15 (22.10) -2.90 -4.7 to 1.2 0.63
Carotid IMT maximum average (mm) 0.94 ± 0.14 0.94 ± 0.13 0.00 -0.01 to 0.01 0.74
Carotid IMT maximum average ≥ 90 mm, n (%) 46 (67.60) 42 (61.80) -5.80 -11 to 21 0.39
Plaques, n (%) 15 (22.10) 15 (22.10) 10 -14 to 14 1.00
ABI 1.10 ± 0.13 1.17 ± 0.08 0.07 0.04 to 0.11 < 0.001
TOD ABI, n (%) 8 (11.80) 2 (3.10) -8.70 -17 to 10 0.03
PWV, (m/s) 9.59 ± 2.32 9.78 ± 2.49 0.19 -0.26 to 0.77 0.33
PWV ≥ 12 m/s, n (%) 10 (15.20) 11 (17.50) 2 -10 to 14 0.63
TOD Vascular, n (%) 25 (37.90) 23 (36.50) -14 -18 to -10 0.75
Renal
GFR CKD-EPI (mL/min/1.73 m2) 87.95 ± 13.06 88.64 ± 15.35 0.69 -2.09 to 3.32 0.65
TOD GFR CKD-EPI ≤ 60 mL/min/1.73 m2, n(/%) 1 (1.50) 3 (4.70) 3 -3 to 15 0.50
Albumin/creatinine (mg/g) 36.09 ± 82.81 34.88 ± 75.98 -1.21 -20.80 to 15.05 0.75
TOD Albumin/creatinine (mg/g), n (%) 11 (16.20) 9 (14.50) -1.70 -15 to 9 0.06
TOD Renal n (%) 13 (20.00) 12 (19.40) -0.60 -0.74 to -0.50 0.63
Heart
Cornell VDP (mmms) 1648.29 ± 654.68 1584.79 ± 522.69 -29.91 -118.71 to 58.88 0.50
TOD Cornell VDP (mmms) patologico, n(%) 7 (10.30) 5 (7.80) -2.50 -12 to 7 0.25
TOD global, n (%) 34 (51.50) 32 (50.80) -0.7 -1.9 to 1.5 0.75
Data for qualitative variables are expressed as N° (%) and quantitative variables as mean ± standard deviation.
IMT: Intima-media thickness; ABI: ankle-brachial index; TOD: Target organ damage: PWV: Pulse wave velocity; GFR: glomerular filtration rate; CKD-EPI: Chronic
Kidney Disease Epidemiology Collaboration; PDV: Voltage-duration product
Table 4 Target Organ damage in Metabolic Syndrome
Variables Basal evaluation Annual review Differences IC 95% p Value
Vascular
Carotid IMT men average (mm) 0.75 ± 0.12 0.76 ± 0.12 0.00 -0.01 to 0.02 0.40
Carotid IMT men average ≥ 90 mm, n (%) 6 (13.60) 5 (11.40) -2.20 -16 to 11 0.62
Carotid IMT maximum average (mm) 0.93 ± 0.15 0.93 ± 0.15 0.00 -0.02 to 0.03 0.63
Carotid IMT maximum average ≥ 90 mm, n (%) 25 (56.80) 23 (52.30) -4.50 -24 to 18 0.39
Plaques, n (%) 3 (6.80) 3 (6.90) 0.1 -10 to 11 1.00
ABI 1.10 ± 0.10 1.15 ± 0.09 0.05 0.01 to 0.09 0.03
TOD ABI, n (%) 1(2.30) 2 (4.70) 2.40 -5 to 10 0.03
PWV, (m/s) 9.34 ± 2.69 8.57 ± 2.22 -0.77 -1.50 to 0.07 0.04
PWV ≥ 12 m/s, n (%) 7 (15.90) 2 (4.70) -11.20 -24 to 12 0.75
TOD Vascular, n (%) 11 (25.00) 6 (14.00) -11 -27 to 54 0.06
Renal
GFR CKD-EPI (mL/min/1.73 m2) 88.57 ± 13.89 87.26 ± 16.03 -1.31 -5.15 to 2.58 0.50
TOD GFR CKD-EPI ≤ 60 mL/min/1.73 m2, n(/%) 0 (0.00) 3 (7.00) 7 -1 to 15 0.25
Albumin/creatinine (mg/g) 17.31 ± 39.04 28.89 ± 133.82 11.58 -30.36 to 55.92 0.55
TOD Albumin/creatinine (mg/g), n (%) 7 (16.30) 1 (2.40) 13.90 -25 to -2 0.06
TOD Renal n (%) 7 (16.30) 5 (11.90) -4.40 -18 to 10 1.00
Heart
Cornell VDP (mmms) 1486.64 ± 457.67 1661.89 ± 536.983 184.22 62.28 to 306.15 0.01
TOD Cornell VDP (mmms) patologico, n(%) 1 (2.30) 4 (9.30) 7 -3 to 17 0.25
TOD global, n (%) 1 (2.30) 4 (9.30) 7 -3 to 17 0.25
Data for qualitative variables are expressed as N° (%) and quantitative variables as mean ± standard deviation.
IMT: Intima-media thickness; ABI: ankle-brachial index; TOD: Target organ damage: PWV: Pulse wave velocity; GFR: glomerular filtration rate; CKD-EPI: Chronic
Kidney Disease Epidemiology Collaboration; PDV: Voltage-duration product
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Page 6 of 9patient age, since in this study the subjects with Meta-
bolic syndrome were comparatively younger [29].
T h em e a nP W Vv a l u e si nt h ed i a b e t i c s( 9 . 5 9m / s e c
at initial measurement and 9.78 m/sec after one year
of follow-up) were similar to those reported by Lacy
et al. [30], and higher than those recorded in popula-
tion-based studies [16,31]. In the patients with meta-
bolic syndrome, the mean PWV decreased from 9.34
to 8.57 m/sec, a situation explained by the increased
use of antihypertensive treatment (from 0.82 to 1.34
drugs per patient), which is presently the most potent
option for reducing arterial stiffness [32]. Likewise,
antihypertensive drug use is the variable explaining
the variability in the differences in the regression
analysis.
The behavior of ABI was similar in both patient
groups, with an increase after one year of follow-up.
Similar data have been published by Ito et al. [33] in
patients with T2DM. However, it must be remembered
that in diabetic patients the standard threshold sensitiv-
ity (0.9) is lower as a result of which the efficiency of
ABI is limited. Moreover, in this group of patients the
sensitivity for values between 0.9-1.3 is low (15-79%)
[34,35]. In the improved results of ABI, one of the
Figure 1 Changes between baseline and evaluation after one
year of follow-up. Changes between baseline and evaluation after
one year of follow-up in target organ damage (a) and other study
variables (b) in subjects with T2DM or Metabolic syndrome,
adjusting the values of the differences to a scale of -100 to 100.
IMT: intima-media thickness; ABI: ankle/brachial index; PWV: pulse
wave velocity; VDP: voltage-duration product; BMI: body mass index;
SBP: systolic blood pressure; DBP: diastolic blood pressure.
Table 5 Factors influencing the differences between the two evaluations of target organ damage in diabetics and
patients with metabolic syndrome, in the multiple regression analysis
Diabetics Metabolic syndrome
b IC 95% p b IC 95% p Value
D-IMT Adjusted R2 = 0.001 D-IMT Adjusted R2 = 0.038
Constant -0.01 -0.09 to 0.09 0.97 constant 0.04 0.06 to 0.14 0.40
Age -0.01 -0.01 to 0.01 0.43 Age -0.01 0.01 to 0.01 0.14
Gender 0.02 -0.01 to 0.05 0.21 Gender 0.02 0.02 to 0.06 0.32
D-PWV Adjusted R
2 = 0.133 D-PWV Adjusted R
2 = 0.235
Constant -1.97 -6.87 to 2.93 0.42 constant 2.57 1.34 to 6.48 0.19
Age 0.04 -0.04 to 0.12 0.28 Age -0.05 0.12 to 0.01 0.09
Gender 0.22 -1.07 to 1.51 0.73 Gender 1.13 0.59 to 2.86 0.19
D-DBP 0.05 0.01 to 0.08 0.01 D-FHTA -1.44 2.39 to -0.50 0.01
D-PDV DE CORNELL
Adjusted R
2 = 0.104
D-PDV DE CORNELL
Adjusted R
2 = 0.258
Constant 124.16 -889.48 to 1137.79 0.80 constant -74.32 -600.14 to 451.49 0.77
Age -2.57 -18.74 to 13.59 0.75 Age 4.63 4.15 to 13.421 0.29
Gender -18.44 -248.79 to 285.66 0.89 Gender -19.19 251.72 to 213.33 0.87
D-DBP 7.89 0.88 to 14.90 0.03 D-FHTA -440.80 139.92 to 741.69 0.01
D-ABI Adjusted R
2 = 0.036 D-ABI Adjusted R
2 = 0.005
Constant -0.095 -0.25 to 0.06 0.22 constant -0.06 0.25 to 0.12 0.51
Age 0.02 0.01 to 0.04 0.12 Age 0.01 0.01 to 0.01 0.36
Gender 0.04 -0.01 to 0.10 0.14 Gender 0.01 0.03 to 0.03 0.23
Dependent variable: D-IMT: difference Intima-media thickness; D-PWV: difference pulse wave velocity; D-PDV DE CORNELL: difference voltage-duration product
CORNELL. D-ABI: difference ankle-brachial index
Adjustment variables:Age; Gender: (male = 1; female = 0).
Independent variables: D-BMI: difference body mass index; D-Fibrinogen: difference fibrinogen; D-HDL: difference high density lipoprotein; D-serum glucose:
difference serum glucose; D-HOMA-IR: difference homeostasis model assessment insulin resistance; D-SBP: difference sistolic blood pressure; D-DBP: difference
diastolic blood pressure. D-FHTA: D-Antihypertensive Drugs; D-FHPL: D-Hypolipidemic drugs.
R2: determination coefficient; p: statistically significant differences (p < 0.05).
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Page 7 of 9possible causes for the increase in the first year is the
decrease in brachial systolic pressure, without an accom-
panying decrease at pedal or tibial artery due to the
atherosclerosis of these patients, in addition to the
between- and within-observer variability there may be
between the two measurements.
The evaluation of left ventricular hypertrophy based
on the Cornell voltage-duration product did not vary
between the two evaluation time points in the diabetic
patients, though it was seen to increase at the second
measurement in the patients with metabolic syndrome.
Apart from the low sensitivity (31%) of electrocardiogra-
phy in detecting left ventricular hypertrophy, the elec-
trocardiographic criteria are of little diagnostic use in
the isolated interpretation of a patient with left ventricu-
lar hypertrophy [8]. In any case, the ELECTROPRES
platform, implemented in several Spanish centers, has
concluded that the criteria of the Lewis index (R-I+ S-
III) and Cornell product ([R-aVL + S-V3] [+ 6 in
women]) [36]were those which detected most cases of
left ventricular hypertrophy.
There were no differences in glomerular filtration rate
estimated with the CKD-EPI equation either between
evaluation timepoints or between groups the values in
all cases being over 85 ml/min/1.73 m
2 and greater than
those recorded in other studies [33,37]. Likewise, we
observed no differences between the two evaluations in
terms of the albumin-creatine index the values being
lower in the subjects with Metabolic syndrome, and also
lower than the values published for diabetic subjects in
our setting [37].
This study has some limitations that must be consid-
ered when interpreting the results obtained. Firstly, the
number of subjects per group, which limits the power of
an analyses made, as well as follow-up limited to the
first year of the study. It also should be taken into
account that selection was not randomized but involved
consecutive sampling, and the two groups are not fully
balanced in terms of age (4 years of difference) - a fact
that may influence the course, though the analyses have
been adjusted for this variable in order to minimize its
influence.
The annual assessment of cardiovascular risk factors
and the decrease in pulse wave velocity was more favor-
able in the patients with metabolic syndrome, probably
influenced by the increased percentage of subjects trea-
ted with antihypertensive and lipid lowering drugs in
this group.
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